Skip to main content

Month: February 2021

Descartes Sets Date to Announce Fiscal 2021 Fourth Quarter and Year-End Financial Results

WATERLOO, Ontario, Feb. 02, 2021 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its fiscal 2021 fourth-quarter and year-end financial results after market close on Wednesday, March 3, 2021.Members of Descartes’ executive management team will host a conference call to discuss the company’s financial results at 5:00 p.m. ET on Wednesday, March 3. Designated numbers are +1 888 465-5079 for North America and +1 416 216-4169 for international, using Passcode 9076129#.The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. Phone conference dial-in or webcast login is required approximately 10 minutes beforehand.Replays of the conference...

Continue reading

Unitil Reports Year-End Earnings

HAMPTON, N.H., Feb. 02, 2021 (GLOBE NEWSWIRE) — Unitil Corporation (NYSE: UTL) (www.unitil.com) today announced Net Income of $32.2 million, or $2.15 in Earnings Per Share, for the year ended December 31, 2020, a decrease of $12.0 million, or $0.82 per share, compared to 2019. In the first quarter of 2019, the Company recognized a one-time net gain of $9.8 million, or $0.66 per share, on the Company’s divestiture of its non-regulated business subsidiary, Usource. The Company’s earnings in 2020 reflect higher gas and electric sales margins and higher operating expenses. The Company estimates that warmer than normal weather negatively affected Net Income by approximately $3.1 million, or $0.20 per share, in 2020. Additionally, the Company estimates that the coronavirus pandemic negatively affected Net Income by approximately $1.4...

Continue reading

Udbytter for 2020 for Investeringsforeningen Danske Invest

I selskabsmeddelelse af 1. december 2020 offentliggjorde foreningen de foreløbige beregnede udbyttesatser.Bestyrelsen har den 2. februar 2021 besluttet nedenstående reviderede udbyttesatser. Herudover angives de tidligere udbetalte aconto udbytter.Udbyttet fragår i kursen på andelene den 3. februar 2021. Den sidste dag for handel med andele inkl. udbytte bliver derfor den 2. februar 2021.  Udbytterne indgår efter fradrag af en eventuel udbytteskat på investors konto den 5. februar 2021.Yderligere oplysninger kan findes på www.danskeinvest.dk.Med venlig hilsenDANSKE INVEST MANAGEMENT A/SRobert Bruun Mikkelstrupadm. direktør

Continue reading

Udbytter for 2020 for Investeringsforeningen Danske Invest Select

I selskabsmeddelelse af 1. december 2020 offentliggjorde foreningen de foreløbige beregnede udbyttesatser.Bestyrelsen har den 2. februar 2021 besluttet nedenstående reviderede udbyttesatser. Herudover angives de tidligere udbetalte aconto udbytter.Udbyttet fragår i kursen på andelene den 3. februar 2021. Den sidste dag for handel med andele inkl. udbytte bliver derfor den 2. februar 2021.  Udbytterne indgår efter fradrag af en eventuel udbytteskat på investors konto den 5. februar 2021.Yderligere oplysninger kan findes på www.danskeinvest.dk.Med venlig hilsenDANSKE INVEST MANAGEMENT A/SRobert Bruun Mikkelstrupadm. direktør

Continue reading

CORRECTING and REPLACING — Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit “µg” were mistakenly represented as “mg.” The corrected release follows:Primary and secondary lung function endpoints metResults support twice-daily dosingVerona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease (“COPD”).Ensifentrine delivered by pMDI met all of the primary and secondary lung function endpoints in the 7 day, Phase 2 clinical trial. The magnitude...

Continue reading

Chart Industries Invests $15 million in Svante Inc. and Signs Commercial Carbon Capture MOU

VANCOUVER, British Columbia and ATLANTA, Feb. 02, 2021 (GLOBE NEWSWIRE) — Svante Inc. and Chart Industries Inc. (“Chart”) (NYSE: GTLS), a leading global manufacturer of liquefaction and cryogenic equipment for the energy and industrial gas markets, have entered into a binding commercial Memorandum of Understanding (“MOU”). The MOU establishes how the companies will explore commercial opportunities as channel to market preferred partners and collaborate to develop an integrated carbon capture solution using Svante’s rapid adsorption technology and Chart’s cryogenic carbon capture technology to make high-purity CO2 products from industrial flue gas streams. The MOU was executed in conjunction with the completion of Chart’s investment in Svante in the amount of $15 million representing under 10% of its capital stock on a fully diluted...

Continue reading

Coloplast delivers a good start to the year with 5% organic growth in Q1 and maintains its financial guidance for 2020/21

Coloplast delivered 5% organic growth, and EBIT increased by 4% to DKK 1,536m, corresponding to an EBIT margin of 32%, in the first quarter of the 2020/21 financial year. The company maintains its financial guidance for 2020/21.Coloplast delivered 5% organic revenue growth in the first three months of the 2020/21 financial year. EBIT amounted to DKK 1,536m, a 4% increase, corresponding to an EBIT-margin of 32% against 31% last year.“Our priorities have been clear throughout the pandemic. We want to keep our employees safe, while continuing to serve our customers, who rely on our products and services to manage their conditions. I am proud of the work that is being done by our many teams across the world to make sure that we continue business operations and continue to support our customers,” says Coloplast CEO Kristian Villumsen and continues: “Despite...

Continue reading

Coloplast leverer en god start på året med 5% organisk vækst i første kvartal og fastholder forventningerne til 2020/21

Coloplast leverede 5% organisk vækst, og driftsresultatet steg 4% til 1.536 mio. kr., svarende til en overskudsgrad på 32%, i første kvartal af regnskabsåret 2020/21. Virksomheden fastholder sine finansielle forventninger til 2020/21.Coloplast leverede en organisk vækst på 5% i de tre første måneder af regnskabsåret 2020/21. Driftsresultatet for kvartalet steg 4% til 1.536 mio. kr., svarende til en overskudsgrad på 32% mod 31% sidste år.“Vi har under pandemien haft helt klare prioriteter. Vi skal værne om vores medarbejderes sikkerhed og samtidigt betjene vores kunder, som er dybt afhængige af vores produkter og services til at håndtere deres kroniske lidelser. Jeg er utrolig stolt af det arbejde, som vores mange medarbejdere udfører verden over for at sikre, at vi kan holde vores forretning kørende og fortsat være der for vores...

Continue reading

Nabis Holdings Inc. Provides Update on Arizona Operations

VANCOUVER, British Columbia, Feb. 02, 2021 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: A2PL) (“Nabis” or the “Company“) today provided an update on Arizona operations.Yesterday, Perpetual Healthcare Inc. received its “Dual License” from the Arizona Department of Health Services, enabling it to sell cannabis products to adult users in addition to continuing to service its established medical clientele. Perpetual intends to commence sales to the “adult use” market as quickly as practicable.Further, PNTM Management Services, LLC (“PNTM”), the plaintiffs in the previously announced lawsuit against the Company’s wholly-owned subsidiary, Nabis AZ LLC have agreed to a stipulation to dismiss after Nabis discharged its US$8.5M deferred payment obligation to PNTM in respect of an asset purchase...

Continue reading

Coloplast A/S – Announcement no. 01/2021 – Interim Financial Report, Q1 2020/21

Q1 2020/21Interim financial results, Q1 2020/21(1 October 2020 – 31 December 2020)Coloplast delivers a good start to the year, guidance for 2020/21 maintainedColoplast delivered 5% organic growth in the first quarter. Reported revenue in DKK was up by 1% to DKK 4,738 million. Exchange rate developments decreased revenue by 4% due to a significant decrease in the value of USD, GBP and several emerging markets currencies, in particular ARS and BRL.Organic growth rates by business area for the first quarter: Ostomy Care 6%, Continence Care 6%, Interventional Urology 5% and Wound & Skin Care 1%.Chronic Care delivered a satisfactory first quarter, primarily driven by solid growth in Emerging markets and the US. Growth in Europe continues to be negatively impacted by the COVID-19 outbreak due to lower growth in new patients, particularly...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.